Welcome to our dedicated page for Grifols S A news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols S A stock.
Grifols, S.A. reports developments tied to its global healthcare business, including plasma-derived medicines, diagnostic technologies, transfusion-medicine solutions and biological supplies for research, clinical trials and pharmaceutical or diagnostic manufacturing. Its business references include Biopharma, Diagnostic, Bio Supplies and other activities such as manufacturing services, research and complementary pharmaceutical products.
Recurring news themes include product and regulatory updates for plasma-protein therapies, such as fibrin sealant for surgical bleeding, and research programs that use plasma assets, AI, proteomics and real-world data. Coverage also includes Chronos-PD work led by Alkahest, shareholder communications on board composition and disclosure, and capital-market topics affecting Grifols' listed shares in Spain and the United States.
Grifols (NASDAQ: GRFS) announced its acquisition of Alkahest, Inc. for $146 million on a debt-free basis. The deal aims to leverage Alkahest's expertise in the human plasma proteome to develop innovative therapies for age-related diseases. The transaction is pending antitrust approval and expected to close in early 2021. Alkahest has identified over 8,000 proteins that could lead to new therapeutics and diagnostics. This acquisition aligns with Grifols' mission to enhance its research and development capabilities in plasma-derived medicines.
Grifols has announced its acquisition of Alkahest, Inc. for $146 million, aimed at enhancing its research and development capabilities for age-related diseases. The transaction, debt-free and requiring no additional financing, is subject to antitrust approval and expected to finalize in early 2021. Alkahest specializes in therapies targeting the aging plasma proteome, with over 8,000 proteins identified, promising innovative therapeutic avenues. This strategic move is anticipated to provide synergies in drug development for unmet medical needs associated with aging.
Grifols has successfully delivered the first batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, aimed at providing passive immunity against COVID-19. This therapy, developed from convalescent plasma, will undergo safety and efficacy trials this summer. Grifols' initiative is backed by collaborations with U.S. health agencies, including the FDA and NIH, with previous experience from the Ebola outbreak enhancing their response. This positions Grifols as a key player in addressing current and future viral threats through innovative therapies.
Grifols announced the publication of the AMBAR study results in a prestigious journal, demonstrating that plasma protein replacement therapy can delay cognitive decline in Alzheimer's patients. The study, which followed patients for 14 months, showed significant improvements compared to a control group, indicating the potential of plasma-derived therapies in addressing Alzheimer's disease. Grifols emphasizes its commitment to expanding research in this area, aiming to develop new therapies for Alzheimer's and other degenerative diseases.
Grifols has acquired a 10% stake in Bloodbuy, a cloud-based marketplace enhancing blood component distribution in the U.S. This strategic investment aims to improve access to vital blood products for hospitals and healthcare providers, addressing supply and demand challenges exacerbated by COVID-19. Grifols will gain a seat on Bloodbuy's Board of Directors to support its growth and gain insights into the blood-component market. Bloodbuy's platform is crucial in connecting blood centers and hospitals, aiming to reduce waste and improve the efficiency of blood supply management.
Grifols has announced a strategic acquisition of a plasma fractionation facility in Montreal, along with 11 collection centers in the U.S., for US$460 million. This move positions Grifols as the only large-scale commercial manufacturer of plasma products in Canada, with a planned fractionation capacity of 1.5 million liters/year. The acquisition aligns with Grifols' commitment to enhancing the availability of plasma-derived medicines and aims to support Canada’s self-sufficiency in healthcare. The transaction is anticipated to close by the end of 2020, pending regulatory approvals.